HTR3A and Cowden syndrome 1: CSTI-300 was shown to be a high-affinity 5-HT3R partial agonist with a good dose-dependent efficacy in a rodent model, representing a potential promising treatment mostly for patients with diarrhea-predominant CS, with less constipation than alosetron [83].